Utah Cancer Specialists-Salt Lake City

Summary

Utah Cancer Specialists-Salt Lake City is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Breast Cancer, Lung Cancer, Pancreatic Cancer, Cancer, Prostate Cancer and other specialties. Utah Cancer Specialists-Salt Lake City is involved with conducting 234 clinical trials across 347 conditions. There are 14 research doctors associated with this hospital, such as Nicholas DiBella, Justin Call, Stephan Kendall, MD, and Ramya Thota.

Top PIs

Clinical Trials running at Utah Cancer Specialists-Salt Lake City

Breast Cancer

Lung Cancer

Ovarian Cancer

Multiple Myeloma

Throat Cancer

Colorectal Cancer

Pancreatic Cancer

Esophageal Cancer

Prostate Cancer

Non-Small Cell Lung Cancer

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Recruiting

2 awards

Phase 3

13 criteria

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

PF-07220060 + Letrozole

for Breast Cancer

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Recruiting

2 awards

Phase 3

4 criteria